secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2024-07-31T23:59:59+00:00
Accession:  0000950170-24-088247
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics appoints Lucy To as CFO effective August 12, 2024
---------------------------------------------------------------------

- Lucy To appointed CFO; Mark Conley reassumes VP Finance role effective August 12.
- To brings 18+ years experience; most recently MD at Wells Fargo Healthcare IB.
- Employment agreement: $475K base, $125K signing bonus, 125K stock options vesting over 4 years.
- Top-line Phase 1 data for T1D drug SAB-142 expected by end of 2024 per press release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000095017024088247/0000950170-24-088247-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000095017024088247/sabs-20240726.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-088247

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer